Is [18F]-DPA-714 PET a Good Marker of Neuroinflammation in Autoimmune Encephalitis?

Abroad (travel likely)RecruitingPHASE2

Conditions

Autoimmune Encephalitis (AE)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University Hospital, Toulouse, France
Contact: Study coordinator (Marie RAFIQ, MD) · rafiq.m@chu-toulouse.fr
Contact: Principal Investigator (Marie rafiq, MD)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases

Relapsing or Refractory Multiple Sclerosis (MS) · Myasthenia Gravis (MG) · Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Abroad (travel likely)RecruitingEARLY_PHASE1

Wuhan, China

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Multiple Sclerosis (MS) · Neuromyelitis Optica Spectrum Disorder (NMOSD) · Autoimmune Encephalitis (AE)

Abroad (travel likely)RecruitingPHASE1

Wuhan, China